NEW BRUNSWICK, N.J. / Apr 22, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein’s 40 th Annual Strategic Decisions Conference (SDC) on Wednesday, May 29 th , at the New York Hilton Midtown, New York, NY. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 1:30 pm (Eastern Time). This live audio webcast will be available to investors and... Read More

NEW BRUNSWICK, N.J. / Apr 16, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.2% increase in the quarterly dividend, from $1.19 per share to $1.24 per share, marking the 62 nd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $4.96 per share compared to the previous rate of $4.76 per share. The next quarterly dividend... Read More

2024 First-Quarter reported sales growth of 2.3% to $21.4 Billion with operational growth of 3.9%* and adjusted operational growth of 4.0%* Adjusted operational growth excluding COVID-19 Vaccine of 7.7%* 2024 First-Quarter Earnings per share (EPS) increased to $2.20 and adjusted EPS increased to $2.71 or 12.4%* Company increasing the midpoint for Full-Year 2024 operational sales 5 and adjusted operational EPS guidance NEW... Read More

NEW BRUNSWICK, N.J. / Apr 08, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15 th , at the InterContinental Barclay Hotel, New York. Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will represent the Company in a session scheduled at 11:00 am (Eastern Time). This live audio webcast will be available to... Read More

Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse Approval is based on results from the Phase 3 CARTITUDE-4 study, in which treatment with CARVYKTI ® in 1-3 prior lines of therapy reduced the risk of disease progression or death by 59 percent compared to standard therapies HORSHAM, Pa. , April 5, 2024... Read More

Enhances Johnson & Johnson’s Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech’s Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss... Read More

NEW BRUNSWICK, N.J. / Apr 04, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to purchase up to 1 million shares of Johnson & Johnson common stock at a price of $151.23 per share in cash. TRC Capital Investment’s offer price of $151.23 per share is approximately 4.12% lower than the... Read More

NEW BRUNSWICK, N.J. / Apr 02, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities Health Care Conference on Tuesday, May 14 th , at the Encore Hotel, Las Vegas, Nevada. John Reed, Executive Vice President, Innovative Medicine, R&D, will represent the Company in a session scheduled at 4:40 pm (Eastern Time). This live audio webcast will be available to investors and other interested... Read More

NEW BRUNSWICK, N.J. / Mar 11, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16 th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and... Read More

Acquisition strengthens Johnson & Johnson’s commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted oncologic therapeutics NEW BRUNSWICK, N.J. / Mar 07, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary... Read More

Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT ® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone in patients with previously untreated NSCLC with EGFR exon 20 insertion mutations National Comprehensive Cancer Network ® (NCCN ® ) updated its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) to recommend... Read More

Biweekly dosing with TECVAYLI ® , the first approved BCMA-targeting bispecific antibody, provides patients with dosing flexibility HORSHAM, Pa. , Feb. 20, 2024 /PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TECVAYLI ® (teclistamab-cqyv) for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in... Read More

NEW BRUNSWICK, N.J. / Feb 14, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13 th , at the Loews Miami Beach Hotel, Miami Beach, FL. Peter Menziuso, Company Group Chairman, Johnson & Johnson Vision will represent the Company in a session scheduled at 10:45 a.m. (Eastern Time). This live audio webcast will be available to... Read More

NEW BRUNSWICK, N.J. / Feb 12, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Global Biopharma Conference on Tuesday, March 12 th , at the Fontainebleau Miami Beach, FL. Joe Wolk, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 1:00 p.m. (Eastern Time). This live audio webcast will be available to investors and other interested... Read More

NEW BRUNSWICK, N.J. / Feb 02, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 45 th Annual Institutional Investors Conference on Tuesday, March 5 th , at the JW Marriott Orlando Grande Lakes, Orlando, FL. Ahmet Tezel, Company Group Chairman, MedTech R&D will represent the Company in a session scheduled at 2:15 p.m. (Eastern Time). This live audio webcast will be available to... Read More

2023 Fourth-Quarter reported sales growth of 7.3% to $21.4 Billion with operational growth of 7.2%* and adjusted operational growth of 5.7%*. Operational growth excluding COVID-19 Vaccine of 10.9%* 2023 Fourth-Quarter Earnings per share (EPS) of $1.70 increasing 39.3% and adjusted EPS of $2.29 increasing by 11.7%* 2023 Full-Year reported sales growth of 6.5% to $85.2 Billion with operational growth of 7.4%* and adjusted... Read More

Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson's Commitment to Oncology Innovation Novel Technology Platform Sets Stage for the Development of Next Generation ADCs and Targeted Oncologic Therapeutics NEW BRUNSWICK, N.J. / Jan 08, 2024 / Business Wire / Johnson & Johnson... Read More

NEW BRUNSWICK, N.J. / Jan 02, 2024 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2024 of $1.19 per share on the company’s common stock. The dividend is payable on March 5, 2024 to shareholders of record at the close of business on February 20, 2024. The ex-dividend date is February 16, 2024. About Johnson & Johnson At Johnson... Read More

NEW BRUNSWICK, N.J. / Dec 11, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, January 23 rd to review fourth-quarter results. Joaquin Duato, Chairman and CEO, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. Investors and other interested parties... Read More

NEW BRUNSWICK, N.J. / Dec 07, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 th , at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time) This live audio webcast will be available to investors and other... Read More

Provides long-term operational sales outlook, including: Enterprise Compound Annual Growth Rate (CAGR) of 5-7% 1* for 2025-2030 Innovative Medicine CAGR of 5-7% 1* for 2025-2030; expects 10+ assets with peak year sales (PYS) 2 potential of $5B+* and another 15+ assets with PYS 2 potential of $1-5B* MedTech in the upper range of its markets, which are growing 5-7% 3 for 2022-2027, with one third of 2027 sales coming from new... Read More

NEW BRUNSWICK, N.J. / Nov 30, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today that Eugene A. Woods, MBA, MHA, Chief Executive Officer of Advocate Health, has been appointed to its Board of Directors. “Mr. Woods is an exceptional addition to Johnson & Johnson’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Mr. Woods has an impressive career of leading... Read More

Innovative investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation Strengthens position in high-growth MedTech segments NEW BRUNSWICK, N.J. / Nov 30, 2023 / Business Wire / Johnson & Johnson MedTech 1 today announced the completion of the acquisition 2 of Laminar, Inc., a privately-held medical device company focused on... Read More

NEW BRUNSWICK, N.J. / Nov 16, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the ‘Company’) will hold an Enterprise Business Review for the investment community on Tuesday, December 5, 2023. During the event, Company leaders will share a detailed review of the Innovative Medicine and MedTech businesses and their respective pipelines as well as discuss the Company’s long-term strategy to deliver sustained growth and... Read More

NEW BRUNSWICK, N.J. / Oct 23, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the Company) announced today that Ashley McEvoy, Executive Vice President, Worldwide Chairman of MedTech, informed the company on October 20, 2023, that she is stepping down from her position to pursue other opportunities. Ms. McEvoy will remain with the Company into Q1 2024 to support a successful transition. Tim Schmid has been appointed... Read More

NEW BRUNSWICK, N.J. / Oct 19, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2023 of $1.19 per share on the company’s common stock. The dividend is payable on December 5, 2023 to shareholders of record at the close of business on November 21, 2023. The ex-dividend date is November 20, 2023. About Johnson & Johnson At... Read More

2023 Third-Quarter reported sales growth of 6.8% to $21.4 Billion with operational growth of 6.4%* and adjusted operational growth of 4.9%*. Operational growth excluding COVID-19 Vaccine of 9.0%* Earnings per share (EPS) of $1.69 increasing 4.3% and adjusted EPS of $2.66 increasing by 19.3%* Company is increasing 2023 full-year guidance midpoints for sales 5 and adjusted EPS NEW BRUNSWICK, N.J. / Oct 17, 2023 / Business Wire... Read More

NEW BRUNSWICK, N.J. / Sep 18, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 17 th to review third-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional... Read More

Brand and visual identity demonstrate the best of Johnson & Johnson’s care and humanity, while capturing the Company’s passion and determination to improve the health of people worldwide NEW BRUNSWICK, N.J. / Sep 14, 2023 / Business Wire / For more than 135 years, Johnson & Johnson (the “Company”) (NYSE: JNJ) has provided health care products and solutions to people worldwide. Now, with its exclusive focus on healthcare... Read More

Company expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and Adjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine Company expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting increased growth of 12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting increased growth of 11.5% at... Read More

NEW BRUNSWICK, N.J. / Aug 23, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced the final results of its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023.... Read More

NEW BRUNSWICK, N.J. / Aug 22, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 21 st Annual Global Healthcare Conference at the Sheraton New York Hotel in New York on Wednesday, September 13 th . Joaquin Duato, Chairman of the Board and Chief Executive Officer and John Reed, Executive Vice President Pharmaceuticals R&D will represent the Company in a session scheduled at 10:10 a.m.... Read More

NEW BRUNSWICK, N.J. / Aug 21, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that, based on preliminary results, its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the... Read More

NEW BRUNSWICK, N.J. / Aug 16, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced the final exchange ratio for its previously announced split-off exchange offer to Johnson & Johnson shareholders to exchange their shares of Johnson & Johnson for shares of common stock of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) currently held by Johnson & Johnson. For each share of Johnson & Johnson common stock that is validly... Read More

NEW YORK , Aug. 9, 2023 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) will be added to the S&P 500 effective prior to the open on a date to be announced conditioned upon the successful completion of a voluntary exchange offer being conducted by S&P 500 & S&P 100 constituent Johnson & Johnson (NYSE: JNJ). Johnson & Johnson announced its intention to split off at least 80.1% of Kenvue shares it owns through a voluntary exchange... Read More

NEW BRUNSWICK, N.J. / Aug 07, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the 2023 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Thursday, September 7 th . Ashley McEvoy, EVP, Worldwide Chairman, MedTech along with executives from Abiomed will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time). This conference call will be... Read More

SKILLMAN, N.J. / Jul 24, 2023 / Business Wire / Kenvue Inc. (NYSE: KVUE) (“Kenvue”) announced that it intends to file a Form S-4 Registration Statement today with the Securities and Exchange Commission (the “SEC”) in connection with Johnson & Johnson’s (NYSE: JNJ) proposed offer to exchange up to 1,533,830,450 shares of Kenvue common stock that it owns, representing 80.1% of the total outstanding shares of Kenvue common... Read More

Separation enhances Company focus on Pharmaceutical and MedTech Research & Development to deliver innovative and differentiated health outcomes Johnson & Johnson shareholders can exchange all, some or none of their shares of Johnson & Johnson common stock for shares of Kenvue Provides Johnson & Johnson shareholders with option for a tax-free exchange for U.S. Federal income tax purposes NEW BRUNSWICK, N.J. / Jul 24, 2023 /... Read More

2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of 8.9%* Earnings per share (EPS) of $1.96 increasing 8.9% and adjusted EPS of $2.80 increasing by 8.1%* Company is increasing 2023 full-year guidance midpoints for adjusted operational sales excluding COVID-19 Vaccine and adjusted... Read More

NEW BRUNSWICK, N.J. / Jul 10, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the UBS MedTech, Tools and Genomics Summit on Tuesday, August 15 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Celine Martin, Company Group Chairman Cardiovascular & Specialty Solutions Group (CSS), Anthony (Tony) Long, VP, Clinical Research, Medical Affairs, Preclinical Research and Jasmina... Read More

NEW BRUNSWICK, N.J. / Jun 06, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Thursday, July 20 th to review second-quarter results. Joaquin Duato, Chairman of the Board and CEO, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. Investors and other... Read More

NEW BRUNSWICK, N.J. / May 10, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Biljana Naumovic, Worldwide Vice President, Oncology, and Peter Lebowitz, Global Therapeutic Head, Oncology, will represent the Company in a session scheduled at 4:20... Read More

NEW BRUNSWICK, N.J. & SKILLMAN, N.J. / May 03, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue’s upsized initial public offering (“IPO”) of 172,812,560 shares of Kenvue’s common stock at a price to the public of $22.00 per share. In addition, Kenvue has granted the underwriters a 30-day option to purchase up... Read More

NEW BRUNSWICK, N.J. / Apr 25, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39 th Annual Strategic Decisions Conference on Wednesday, May 31 st , at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). This webcast will be available to investors and... Read More

NEW BRUNSWICK, N.J. / Apr 24, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (“IPO”) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600... Read More

Leadership committee seeks to bring resolution to decade-long legal battle ST. LOUIS , April 21, 2023 /PRNewswire/ -- Lawyers representing approximately 55,000 plaintiffs in the litigation against Johnson & Johnson (NYSE: JNJ) over its cancer-causing talcum powder products have formed an Ad Hoc Committee to support an $8.9 billion deal that would end a decade-long legal battle against the pharmaceutical giant. To view the ad... Read More

2023 First-Quarter reported sales growth of 5.6% to $24.7 Billion with operational growth of 9.0%* and adjusted operational growth of 7.6%* 2023 First-Quarter basic loss per share of ($0.03) decreasing 101.6% due to a special one-time charge, with adjusted earnings per share (EPS) of $2.68 increasing by 0.4%* Company is increasing 2023 full-year guidance midpoints for adjusted operational sales and adjusted operational EPS... Read More

LTL’s Reorganization Plan Has Significant Support From Claimants The Plan Includes LTL’s Present Value Commitment of $8.9 Billion Payable Over 25 Years For Complete Resolution NEW BRUNSWICK, N.J. / Apr 04, 2023 / Business Wire / Johnson & Johnson (NYSE:JNJ) (the Company) today announced that its subsidiary LTL Management LLC (LTL) has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a... Read More

NEW BRUNSWICK, N.J. / Mar 15, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 18 th to review first-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional... Read More

BEERSE, Belgium / Mar 15, 2023 / Business Wire / The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice. The first-in-class antiviral, which was shown to be safe and well tolerated in a Phase 1 first-in-human clinical... Read More

NEW BRUNSWICK, N.J. / Mar 08, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson, priced an offering of the following series of senior unsecured notes in an aggregate principal amount of $7.75 billion (each series of notes collectively, the “Notes”): Principal Coupon Maturity Date $750,000,000 5.500% Senior Notes due 2025... Read More

NEW BRUNSWICK, N.J. / Feb 14, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) announced today that Paula A. Johnson, MD, MPH, President of Wellesley College, has been appointed to its Board of Directors. “I am excited to welcome Dr. Paula Johnson to Johnson & Johnson’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Paula is an impressive leader, physician-scientist,... Read More

NEW BRUNSWICK, N.J. / Feb 14, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Barclays Global HealthCare Conference on Tuesday, March 14 th , at the Loews Miami Beach Hotel, Miami Beach, Florida. Aldo Denti, Company Group Chairman DePuy Synthes and Peter Menziuso, Company Group Chairman, Vision will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time). This live audio webcast... Read More

NEW BRUNSWICK, N.J. / Feb 13, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) (the Company) today announced the appointment of John Reed, M.D., Ph.D., to the Company’s Executive Committee as Executive Vice President of Pharmaceuticals, R&D. Dr. Reed previously served as Executive Vice President, Global Head of Research and Development for Sanofi and brings more than 35 years of biomedical research leadership to the... Read More

NEW BRUNSWICK, N.J. / Feb 02, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 43 rd Annual HealthCare Conference on Tuesday, March 7 th , at the Boston Marriott Copley Place, Boston, MA. Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 11:10 a.m. (Eastern Time). This live audio webcast will be available to investors... Read More

2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%* 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 increasing by 10.3%* 2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by... Read More

Johnson & Johnson (NYSE: JNJ) will participate in the SVB Securities Global Biopharma Conference on Wednesday, February 15 th . Biljana Naumovic, Worldwide Vice President, Oncology and Peter Lebowitz, Global Therapeutic Head, Oncology will represent the Company in a virtual session scheduled at 1:00 p.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the... Read More

Broadens MedTech Portfolio with World Leading Solutions for Heart Recovery Strengthens Position in High-Growth MedTech Segments Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment. “We are... Read More

Results from the pivotal MonumenTAL-1 study, including first results from the Phase 2 portion, featured at the 2022 ASH Annual Meeting 1 BEERSE, BELGIUM, Dec. 10, 2022 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1/2 MonumenTAL-1 study of talquetamab, an investigational, off-the-shelf (ready to use) bispecific T-cell engager antibody. 1 , 2 , 3... Read More

Alex Gorsky to Step Down After 30-Year Career at Johnson & Johnson NEW BRUNSWICK, N.J.--( BUSINESS WIRE )-- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has elected Chief Executive Officer, Mr. Joaquin Duato, to assume the additional position of Chairman, effective in January 2023. Mr. Duato succeeds Mr. Alex Gorsky, who will step down from his role as Executive Chairman following a brief... Read More

Strengthens Johnson & Johnson’s MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson’s Near- and Long-Term Sales and Earnings Growth; Accretive to Adjusted Earnings beginning in 2024 Conference Call at 8:00 a.m. ET To Discuss Details of the Transaction NEW BRUNSWICK, N.J. & DANVERS,... Read More